Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

p53 is not directly relevant to the response of Polo-like kinase 1 inhibitors

1 Feb 2012

Abstract excerpt

Polo-like kinase 1 (Plk1) is elementary for cell proliferation and its deregulation is involved in tumorigenesis. Plk1 has been established as one of the most attractive targets for molecular cancer therapy. In fact, multiple small molecule inhibitors targeting either the kinase domain or the Polo-box binding domain (PBD) of Plk1 have been identified and intensively investigated. Intriguingly, Plk1 depletion...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Cancer-related Molecular Pathways
Share to Microtubule and mitosis dynamics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22262171
DOI: 10.4161/cc.11.3.19076

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

p53 is not directly relevant to the response of Polo-like kinase 1 inhibitorsPMID 22262171Read ↗

Polo-like kinase 1 inhibitors, mitotic stress and the tumor suppressor p53.Semantic proximity Read ↗

Battle of the eternal rivals: restoring functional p53 and inhibiting Polo-like kinase 1 as cancer therapySemantic proximity Read ↗

Polo-like kinase1 (Plk1) knockdown enhances cisplatin chemosensitivity via up-regulation of p73α in p53 mutant human epidermoid squamous carcinoma cells.Semantic proximity Read ↗

Present and Future Perspective on PLK1 Inhibition in Cancer TreatmentSemantic proximity Read ↗

A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53.Semantic proximity Read ↗

The Role of Polo-like Kinase 1 in Carcinogenesis: Cause or Consequence?Semantic proximity Read ↗

Inhibition of Polo-like kinase 1 (PLK1) triggers cell apoptosis via ROS-caused mitochondrial dysfunction in colorectal carcinomaSemantic proximity Read ↗

Mutant p53 drives cancer chemotherapy resistance due to loss of function on activating transcription of PUMASemantic proximity Read ↗

The balance of Polo-like kinase 1 in tumorigenesisSemantic proximity Read ↗

Small Interfering RNA–Mediated Polo-Like Kinase 1 Depletion Preferentially Reduces the Survival of p53-Defective, Oncogenic Transformed Cells and Inhibits Tumor Growth in AnimalsSemantic proximity Read ↗

Sensitivity of TP53-Mutated Cancer Cells to the Phytoestrogen Genistein Is Associated With Direct Inhibition of Plk1 Activity.Semantic proximity Read ↗

Polo-like kinase 2 targeting as novel strategy to sensitize mutant p53-expressing tumor cells to anticancer treatments.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.